BIOHIT OYJ STOCK EXCHANGE RELEASE ON 10 JUNE 2010 AT 03:15 PM CHANGES IN BIOHIT OYJ'S MANAGEMENT TEAM The Liquid Handling Management Team of Biohit Oyj will be reorganized as of July 1st 2010. The reform, based on the company's operational processes, reflects the new approach to make the business planning and operations more efficient. The new Management Team will include the following members and functions: Jussi Heiniö (President & CEO as of June 10th 2010); Erkki Vesanen (Product Life Cycle Management); Kalle Härkönen (Operations); Jukka-Pekka Haapalahti (Sales and Marketing); Seppo Riikonen (Quality and Risk Management); Tiina Hankonen (Finance, ICT and HR); and Josefin Hoviniemi (Communications). Jussi Heiniö President & CEO Biohit Oyj Further information: Jussi Heiniö Tel: +358-9-773 861 Email: jussi.heinio@biohit.com Distribution: NASDAQ OMX Helsinki Oy Central storage facility (www.oam.fi) Press www.biohit.com About Biohit Oyj Established in 1988, Biohit Oyj is a Finnish biotechnology company, acting on the global market. Biohit's operations are based on a goal-oriented and long-term innovation and patenting strategy. Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective liquid handling solutions for laboratory work as well as diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract. Biohit has two business segments: liquid handling and diagnostics. Liquid handling products include electronic and mechanical pipettes, disposable tips as well as pipette maintenance and calibration services for research institutions, healthcare and industrial laboratories. The diagnostics business comprises products and analysis systems for the early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and H. pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of intestinal bleeding that indicates a risk of colorectal cancer. The Acetium innovation reduces carcinogenic acetaldehyde in anacidic stomachs. The Biohit Group employs around 390 people. The company is headquartered in Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia, India, China, Japan and the USA, as well as a representative office in Singapore. Additionally, Biohit's products are sold by approximately 450 distributors in 70 countries. Biohit's series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small cap/Healthcare since 1999. Read more at www.biohit.com